hydroxyurea has been researched along with deferoxamine in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (30.56) | 18.7374 |
| 1990's | 5 (13.89) | 18.2507 |
| 2000's | 9 (25.00) | 29.6817 |
| 2010's | 11 (30.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Ganeshaguru, K; Hoffbrand, AV; Hooton, JW; Tattersall, MH | 1 |
| Holmes, KT; Hunt, NH; King, NJ; Lean, CL | 1 |
| Hedley, D; Musgrove, E; Rugg, C; Taylor, I | 1 |
| Advani, SH; Basrur, VS; Chitnis, MP; Satyamoorthy, K | 1 |
| Cohen, A; Estrov, Z; Freedman, MH; Gelfand, EW; Kaplinsky, C | 1 |
| Bergeron, RJ; Ingeno, MJ | 1 |
| Ganeshaguru, K; Hoffbrand, AV; Tattersall, MH; Tripp, E | 1 |
| Bacon, PE; Cory, JG; Sato, A | 1 |
| Bacon, PE; Carter, GL; Cory, JG; Sato, A | 2 |
| Cory, JG; Montgomery, JA; Sato, A | 1 |
| Cory, JG; Lasater, L; Sato, A | 1 |
| Cabantchik, ZI; Libman, J; Lytton, SD; Mester, B; Shanzer, A | 1 |
| Ajchenbaum, F; Ando, K; DeCaprio, JA; Griffin, JD | 1 |
| Kasiske, BL; Keane, WF; Kim, Y; O'Donnell, MP | 1 |
| Fukuchi, K; Gomi, K; Nakamaki, T; Tomoyasu, S; Tsuruoka, N | 1 |
| Hagar, RW; Vichinsky, EP | 1 |
| Georgiou, NA; Marx, JJ; Nottet, HS; Oudshoorn, M; van Asbeck, BS; van der Bruggen, T | 1 |
| Brissot, P; Cannie, I; Chouteau, P; Gripon, P; Guguen-Guillouzo, C; Le Seyec, J; Lescoat, G; Saulier-Le Dréan, B | 1 |
| Berg, PE; Eskenazi, AE; Fan, L; Frantz, CN; Frick, KK; Ikegaki, N; Iyer, J; Kennett, RH; Wada, RK; Zhu, S | 1 |
| Gao, J; Richardson, DR | 1 |
| Antholine, WE; Chitambar, CR; Green, DA; Richardson, DR; Wong, SJ | 1 |
| Alebouyeh, M; Haddad-Deylami, H; Moussavi, F; Vossough, P | 1 |
| Choi, OR; Kim, HS; Kwak, IH; Lim, IK; Ryu, MS | 1 |
| Andreani, M; Gaziev, J; Lucarelli, G; Polchi, P; Sodani, P | 1 |
| Terpos, E; Voskaridou, E | 1 |
| Balocco, M; Carrara, P; Forni, GL; Olcese, F; Pinto, V; Soldà, A; Strada, P | 1 |
| Adly, AA; Ismail, EA; Mokhtar, GM; Tantawy, AA | 1 |
| Barrette, S; Files, B; Habr, D; Minniti, CP; Torres, M; Vichinsky, E; Zhang, Y | 1 |
| Cohen, AR; Davis, BR; Heeney, MM; Kwiatkowski, JL; Lee, MT; Odame, I; Owen, WC; Pressel, S; Rogers, ZR; Schultz, WH; St Pierre, T; Ware, RE; Wood, JC | 1 |
| Ghosh, K | 1 |
2 review(s) available for hydroxyurea and deferoxamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Major changes in sickle cell disease.
Topics: Blood Transfusion; Bone Marrow Transplantation; Deferoxamine; Enzyme Inhibitors; Fetal Hemoglobin; Genetic Therapy; Hemoglobin SC Disease; Humans; Hydroxyurea; Imidazoles; Life Expectancy; Risk Factors | 2000 |
3 trial(s) available for hydroxyurea and deferoxamine
| Article | Year |
|---|---|
Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening.
Topics: Adolescent; Adult; beta-Thalassemia; Chelating Agents; Child; Child, Preschool; Combined Modality Therapy; Deferoxamine; Erythrocyte Transfusion; Erythropoiesis; Facial Bones; Female; Genetic Heterogeneity; Genetic Testing; Genotype; Globins; Humans; Hydroxyurea; Iran; Male; Polymorphism, Restriction Fragment Length; Splenectomy | 2004 |
Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
Topics: Acute Kidney Injury; Adolescent; Adult; Anemia, Sickle Cell; Benzoates; Cellulitis; Chelation Therapy; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Deferasirox; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Hydroxyurea; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Prospective Studies; Transfusion Reaction; Triazoles; Young Adult | 2013 |
Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Biological Assay; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Humans; Hydroxyurea; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Stroke; Transfusion Reaction; Triazoles; Ultrasonography, Doppler, Transcranial | 2015 |
31 other study(ies) available for hydroxyurea and deferoxamine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells.
Topics: Anemia, Hypochromic; Deferoxamine; Deoxyribonucleosides; DNA; Female; Humans; Hydroxyurea; Lymphocyte Activation; Lymphocytes; Male; Ribonucleotide Reductases; Thymidine; Thymidine Kinase; Time Factors | 1976 |
Development of the "activated" high resolution 1H MR spectrum in murine T cells and B cells occurs in G1 phase of the cell cycle.
Topics: Adenocarcinoma; Animals; B-Lymphocytes; Cells, Cultured; Deferoxamine; G1 Phase; Hydroxyurea; Lymphocyte Activation; Magnetic Resonance Spectroscopy; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C57BL; Rats; Spleen; T-Lymphocytes; Thymidine; Tritium; Tumor Cells, Cultured | 1990 |
Modulation of transferrin receptor expression by inhibitors of nucleic acid synthesis.
Topics: Animals; Cell Line; Cell Survival; Deferoxamine; DNA Replication; Flow Cytometry; Fluorescence; Humans; Hydroxyurea; Interphase; Iron; Leukemia; Melanoma; Mice; Receptors, Cell Surface; Receptors, Transferrin; RNA | 1985 |
Potentiation of hydroxyurea cytotoxicity in human chronic myeloid leukemia cells by iron-chelating agent.
Topics: 2,2'-Dipyridyl; Antineoplastic Combined Chemotherapy Protocols; Deferoxamine; Drug Synergism; Edetic Acid; Humans; Hydroxybenzoates; Hydroxyurea; In Vitro Techniques; Leukemia, Myeloid; Pyridines | 1986 |
Effect of deferoxamine on DNA synthesis, DNA repair, cell proliferation, and differentiation of HL-60 cells.
Topics: Antigens, Surface; Benzamides; Cell Cycle; Cell Differentiation; Deferoxamine; DNA Repair; DNA, Neoplasm; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Methylnitronitrosoguanidine; Neoplasm Proteins; Ribonucleotide Reductases; RNA, Neoplasm; Tumor Cells, Cultured | 1987 |
Microbial iron chelator-induced cell cycle synchronization in L1210 cells: potential in combination chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Division; Cell Survival; Deferoxamine; Hydroxyurea; Iron Chelating Agents; Kinetics; Leukemia L1210; Mice; Oxazoles | 1987 |
Proceedings: Effect of iron deficiency on DNA synthesis.
Topics: Adenosine Triphosphate; Bone Marrow; Bone Marrow Cells; Deferoxamine; Deoxyribonucleotides; DNA; Humans; Hydroxyurea; In Vitro Techniques; Iron; Lymphocytes; Ribonucleotide Reductases | 1974 |
Studies on the differential mechanisms of inhibition of ribonucleotide reductase by specific inhibitors of the non-heme iron subunit.
Topics: Anaerobiosis; Animals; Catalase; Cell Division; Cells, Cultured; Deferoxamine; Guanazole; Humans; Hydroxyurea; Isoenzymes; Isoquinolines; Leukemia L1210; Peroxidase; Peroxidases; Pyrazoles; Quinolines; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; Triazoles | 1984 |
Effects of biochemical modulation of drug combinations directed at the ribonucleotide reductase site on leukemia L1210 cell growth in culture.
Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cells, Cultured; Deferoxamine; Deoxyadenosines; Drug Synergism; Hydroxyurea; Leukemia L1210; Pyrazoles; Ribonucleotide Reductases | 1983 |
Synergistic inhibition of leukemia L1210 cell growth in vitro by combinations of 2-fluoroadenine nucleosides and hydroxyurea or 2,3-dihydro-1H-pyrazole[2,3-a]imidazole.
Topics: Animals; Cell Survival; Cytidine; Deferoxamine; Deoxyadenosines; Deoxycytidine; Drug Synergism; Hydroxyurea; Kinetics; Leukemia L1210; Mice; Pyrazoles; Vidarabine | 1984 |
Effects of combinations of drugs having different modes of action at the ribonucleotide reductase site on growth of L1210 cells in culture.
Topics: Adenine; Animals; Antineoplastic Agents; Deferoxamine; Deoxyadenosines; Hydroxyurea; Kinetics; Leukemia L1210; Mice; Pyrazoles; Ribonucleotide Reductases | 1982 |
Effect of iron-chelating agents on inhibitors of ribonucleotide reductase.
Topics: Animals; Carcinoma, Ehrlich Tumor; Chelating Agents; Deferoxamine; Edetic Acid; Female; Guanazole; Hydroxyurea; Iron Chelating Agents; Mice; Mice, Inbred ICR; Oxyquinoline; Ribonucleotide Reductases | 1981 |
Mode of action of iron (III) chelators as antimalarials: II. Evidence for differential effects on parasite iron-dependent nucleic acid synthesis.
Topics: Adenosine Triphosphate; Animals; Antimalarials; Deferoxamine; DNA, Protozoan; Erythrocytes; Ferric Compounds; Hydroxamic Acids; Hydroxyurea; Iron Chelating Agents; Plasmodium falciparum; Protozoan Proteins | 1994 |
Independent regulation of human D-type cyclin gene expression during G1 phase in primary human T lymphocytes.
Topics: Cell Division; Cells, Cultured; Cyclin D1; Cyclins; Deferoxamine; G1 Phase; Gene Expression Regulation; Humans; Hydroxyurea; Interleukin-2; Oncogene Proteins; Phosphotransferases; RNA, Messenger; T-Lymphocytes | 1993 |
Oxidative modification of low-density lipoproteins by mesangial cells.
Topics: Antioxidants; Arachidonic Acid; Butylated Hydroxytoluene; Catalase; Cell Division; Cells, Cultured; Cyclooxygenase Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Deferoxamine; DNA Replication; Glomerular Mesangium; Glomerulosclerosis, Focal Segmental; Humans; Hydroxyurea; Indomethacin; Ketoconazole; Lipoproteins, LDL; Lipoxygenase Inhibitors; Masoprocol; Oxidation-Reduction; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances | 1993 |
DNA damage induces p21 protein expression by inhibiting ubiquitination in ML-1 cells.
Topics: Acetylcysteine; Cell Nucleus; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Proteinase Inhibitors; Cytarabine; Deferoxamine; DNA Damage; Etoposide; Gene Expression Regulation; Hydroxyurea; Polyribosomes; RNA, Messenger; Tumor Cells, Cultured; Ubiquitins | 1998 |
The effect of deoxynucleosides on cell proliferation of peripheral blood lymphocytes treated with deferoxamine or hydroxyurea.
Topics: Antisickling Agents; Cell Division; Cells, Cultured; Chelating Agents; Deferoxamine; Deoxyadenosines; Drug Interactions; Humans; Hydroxyurea; Lymphocytes | 2000 |
Inhibition of hepatitis B virus production associated with high levels of intracellular viral DNA intermediates in iron-depleted HepG2.2.15 cells.
Topics: Cell Cycle; Cell Line; Deferoxamine; DNA, Viral; Hepatitis B virus; Humans; Hydroxyurea; Iron; RNA, Messenger; RNA, Viral; Virus Replication | 2001 |
Inhibition of N-myc expression and induction of apoptosis by iron chelation in human neuroblastoma cells.
Topics: Aphidicolin; Apoptosis; Deferoxamine; Gene Expression; Gene Expression Regulation, Neoplastic; Genes, myc; Genes, Reporter; Humans; Hydroxyurea; Inhibitory Concentration 50; Iron; Iron Chelating Agents; Neuroblastoma; Promoter Regions, Genetic; Proto-Oncogene Proteins c-myc; Proto-Oncogenes; RNA, Messenger; Substrate Specificity; Transcription, Genetic; Tumor Cells, Cultured | 2001 |
The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression.
Topics: Antineoplastic Agents; Cell Cycle; Cyclins; Deferoxamine; Female; Genes, Retinoblastoma; Humans; Hydroxyurea; Iron; Iron Chelating Agents; Isoniazid; Pyridoxal; Structure-Activity Relationship; Tumor Cells, Cultured | 2001 |
Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase.
Topics: Antineoplastic Agents; Cell Division; Deferoxamine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Hydroxyurea; Iron Chelating Agents; Isoniazid; Mutation; Protein Subunits; Ribonucleotide Reductases; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
Nuclear accumulation of globular actin as a cellular senescence marker.
Topics: Actin Depolymerizing Factors; Actins; Cell Nucleus; Cells, Cultured; Cellular Senescence; Deferoxamine; Diploidy; Fibroblasts; Humans; Hydrogen Peroxide; Hydroxyurea; Immunohistochemistry; Microfilament Proteins | 2004 |
Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up.
Topics: Adolescent; Adult; Azathioprine; Bone Marrow Transplantation; Busulfan; Chelation Therapy; Clinical Protocols; Combined Modality Therapy; Comorbidity; Deferoxamine; Disease-Free Survival; Erythrocyte Transfusion; Erythropoietin; Female; Follow-Up Studies; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Hemosiderosis; Humans; Hydroxyurea; Immunosuppressive Agents; Iron Chelating Agents; Life Tables; Liver Cirrhosis; Male; Phlebotomy; Postoperative Complications; Survival Analysis; Thalassemia; Transfusion Reaction; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
Treatment options for thalassemia patients with osteoporosis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Calcitonin; Clinical Trials as Topic; Deferoxamine; Diphosphonates; Hormone Replacement Therapy; Humans; Hydroxyurea; Iron Chelating Agents; Iron Overload; Osteoporosis; Thalassemia | 2010 |
Manual erythroexchange for chronic transfusion therapy in patients with sickle cell syndromes unresponsive to hydroxyurea: a long-term follow-up.
Topics: Anemia, Sickle Cell; Blood Transfusion, Autologous; Deferoxamine; Erythrocyte Transfusion; Humans; Hydroxyurea; Longitudinal Studies; Plasma Exchange | 2010 |
Clinicopathological and radiological study of Egyptian β-thalassemia intermedia and β-thalassemia major patients: relation to complications and response to therapy.
Topics: Absorptiometry, Photon; Adolescent; Adult; Antisickling Agents; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferoxamine; Echocardiography; Egypt; Female; Follow-Up Studies; Heart Diseases; Humans; Hydroxyurea; Hypertension, Pulmonary; Male; Osteoporosis; Outcome Assessment, Health Care; Quality of Life; Siderophores; Young Adult | 2011 |
Iron chelators or therapeutic modulators of iron overload: Are we anywhere near ideal one?
Topics: Animals; beta-Thalassemia; Chelating Agents; Deferiprone; Deferoxamine; Humans; Hydroxyurea; Iron Overload; Myelodysplastic Syndromes; Transfusion Reaction | 2018 |